Jonathan E. Rosenberg

Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer

BackgroundThe standard of care for patients with muscle-invasive bladder cancer continues to evolve. Whether perioperative durvalumab, with or without tremelimumab, plus neoadjuvant enfortumab vedotin is effective in such patients is unknown. MethodsIn this phase 3 open-label tri...

Mutational Signatures and Hypermutation Phenotypes Define Bladder Cancers Arising in Waterpipe and Cigarette Smokers

Abstract Bladder cancer is a major malignancy worldwide. Although cigarette smoking is the leading modifiable risk factor, the contribution of waterpipe smoking (WPS), which is increasingly popular globally and often misperceived as safer, remains unclear. In 2019, Lebanese males...